Cg Oncology Inc (NASDAQ:CGON) shares, rose in value on Friday, March 07, with the stock price down by -1.00% to the previous day’s close as strong demand from buyers drove the stock to $26.72.
Actively observing the price movement in the last trading, the stock closed the session at $26.99. Referring to stock’s 52-week performance, its high was $46.99, and the low was $23.91. On the whole, CGON has fluctuated by -11.87% over the past month.
With the market capitalization of Cg Oncology Inc currently standing at about $2.05 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 102.93k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CGON’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CGON currently trading nearly -0.76% and -6.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 46.16, while the 7-day volatility ratio is showing 7.36% which for the 30-day chart, stands at 5.65%. Furthermore, Cg Oncology Inc (CGON)’s beta value is 1.08, and its average true range (ATR) is 1.54.
A comparison of Cg Oncology Inc (CGON) with its peers suggests the former has fared considerably weaker in the market. CGON showed an intraday change of -1.00% in last session, and over the past year, it shrunk by -35.60%%.
Data on historical trading for Cg Oncology Inc (NASDAQ:CGON) indicates that the trading volumes over the past 3 months, they’ve averaged 700.73K. According to company’s latest data on outstanding shares, there are 67.54 million shares outstanding.
Nearly 39.96% of Cg Oncology Inc’s shares belong to company insiders and institutional investors own 66.62% of the company’s shares. The stock has fallen by -6.83% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CGON stock heading into the next quarter.
